NasdaqCM - Nasdaq Real Time Price USD
Liquidia Corporation (LQDA)
At close: 4:00 PM EST
After hours: 4:48 PM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 1 | 3 |
| Avg. Estimate | -0.4 | -0.49 | -1.63 | -1.26 |
| Low Estimate | -0.42 | -0.49 | -1.63 | -1.62 |
| High Estimate | -0.39 | -0.49 | -1.63 | -0.66 |
| Year Ago EPS | -0.42 | -0.39 | -1.17 | -1.63 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 3 | 10 | 10 |
| Avg. Estimate | 4.63M | 4.16M | 15.87M | 49.25M |
| Low Estimate | 3.19M | 3.2M | 14.27M | 27.03M |
| High Estimate | 6.84M | 5M | 18M | 66.7M |
| Year Ago Sales | 4.53M | 2.97M | 17.49M | 15.87M |
| Sales Growth (year/est) | 2.27% | 39.86% | -9.24% | 210.27% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.23 | -0.28 | -0.33 | -0.4 |
| EPS Actual | -0.42 | -0.39 | -0.37 | -0.39 |
| Difference | -0.19 | -0.11 | -0.04 | 0.01 |
| Surprise % | -78.72% | -37.02% | -12.12% | 2.24% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.4 | -0.49 | -1.63 | -1.26 |
| 7 Days Ago | -0.43 | -0.52 | -1.7 | -1.31 |
| 30 Days Ago | -0.43 | -0.52 | -1.7 | -1.31 |
| 60 Days Ago | -0.43 | -0.52 | -1.7 | -1.31 |
| 90 Days Ago | -0.26 | -0.3 | -1.49 | -0.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | 1 |
| Up Last 30 Days | 1 | -- | -- | 1 |
| Down Last 7 Days | -- | 1 | 1 | -- |
| Down Last 30 Days | -- | 1 | 2 | -- |
Growth Estimates
| CURRENCY IN USD | LQDA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 3.97% | -- | -- | 5.00% |
| Next Qtr. | -25.48% | -- | -- | 12.00% |
| Current Year | -39.04% | -- | -- | 2.10% |
| Next Year | 22.50% | -- | -- | 12.20% |
Upgrades & Downgrades
| Initiated | Scotiabank: Sector Outperform | 10/16/2024 |
| Initiated | LifeSci Capital: Outperform | 10/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/23/2024 |
| Reiterates | Needham: Buy to Buy | 8/22/2024 |
| Maintains | BTIG: Buy to Buy | 8/20/2024 |
| Maintains | B of A Securities: Buy to Buy | 8/20/2024 |
Related Tickers
UTHR United Therapeutics Corporation
372.89
+1.51%
VRNA Verona Pharma plc
38.81
+2.51%
ABUS Arbutus Biopharma Corporation
3.5100
+1.45%
TARS Tarsus Pharmaceuticals, Inc.
48.24
+3.97%
DAWN Day One Biopharmaceuticals, Inc.
13.72
+2.85%
MLYS Mineralys Therapeutics, Inc.
12.49
+5.22%
MREO Mereo BioPharma Group plc
3.7200
+1.09%
VRCA Verrica Pharmaceuticals Inc.
0.9945
+0.45%
CGEM Cullinan Therapeutics, Inc.
12.54
+2.62%
PTGX Protagonist Therapeutics, Inc.
46.46
+11.55%